'Muddied' data dampens Bayer's ROCKET
This article was originally published in Scrip
Executive Summary
Bayer and Johnson & Johnson have finally published data from the ROCKET AF study of their recently-approved oral anticoagulant Xarelto (rivaroxaban) compared with warfarin for stroke prevention in patients with atrial fibrillation (AF).